Reusing cytostatics in a centralised pharmacy preparation unit

Farmacia Hospitalaria (English Edition) Pub Date : 2011-01-01 DOI:10.1016/S2173-5085(11)70011-9

S. Ramos Linares, J. Merino Alonso, N. Román González, E. Tévar Alfonso, P. Díaz Ruíz, M. Gorchs Molist

{"title":"Reusing cytostatics in a centralised pharmacy preparation unit","authors":"S. Ramos Linares, J. Merino Alonso, N. Román González, E. Tévar Alfonso, P. Díaz Ruíz, M. Gorchs Molist","doi":"10.1016/S2173-5085(11)70011-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To measure and provide an economic assessment of the preparations returned to a centralised cytostatic drug preparation unit, analyse reasons for their return, propose measures for minimising returns and assess their impact on the Medical Oncology division's outpatient services.</p></div><div><h3>Methods</h3><p>This prospective study contained two phases. During the first, we registered all returns, motives, cases of reuse and costs. In the second phase, we analysed returns at the Oncology outpatient division after having adopted measures to minimise the returns.</p></div><div><h3>Results</h3><p>During the first phase, 218 preparations (worth € 51,131) were returned. The Oncology Day Hospital returned 1% of the preparations worth 1% of the total value; during the second phase, these figures were 0.56% of the preparations and 0.14% of the total value.</p></div><div><h3>Conclusions</h3><p>Favouring reporting on and identifying expensive treatments with little stability and using returned preparations as a quality indicator for Oncology has improved management of the central cystostatic preparation unit</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"35 2","pages":"Pages 70-74"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(11)70011-9","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508511700119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective

To measure and provide an economic assessment of the preparations returned to a centralised cytostatic drug preparation unit, analyse reasons for their return, propose measures for minimising returns and assess their impact on the Medical Oncology division's outpatient services.

Methods

This prospective study contained two phases. During the first, we registered all returns, motives, cases of reuse and costs. In the second phase, we analysed returns at the Oncology outpatient division after having adopted measures to minimise the returns.

Results

During the first phase, 218 preparations (worth € 51,131) were returned. The Oncology Day Hospital returned 1% of the preparations worth 1% of the total value; during the second phase, these figures were 0.56% of the preparations and 0.14% of the total value.

Conclusions

Favouring reporting on and identifying expensive treatments with little stability and using returned preparations as a quality indicator for Oncology has improved management of the central cystostatic preparation unit

查看原文本刊更多论文

在集中制剂单位重复使用细胞抑制剂

目的对某集中细胞抑制剂制剂单位退回制剂进行计量和经济评估，分析退回原因，提出减少退回的措施，并评估其对肿瘤内科门诊服务的影响。方法前瞻性研究分为两个阶段。在第一阶段，我们记录了所有的退货、动机、再利用案例和成本。在第二阶段，我们分析了肿瘤门诊部门在采取措施尽量减少回报后的回报。结果在第一阶段，218份制剂(价值51,131欧元)被退回。肿瘤日间医院退还了总价值1%的制剂的1%;在第二阶段，这些数字占制剂的0.56%，占总价值的0.14%。结论重视报告和识别价格昂贵但稳定性差的治疗方法，并将退回制剂作为肿瘤的质量指标，改善了中央抑囊制剂单位的管理

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Farmacia Hospitalaria (English Edition)

自引率

0.00%

发文量